Naturalistic Follow-up after a Trial of Medications for Opioid Use Disorder: Medication Status, Opioid Use, and Relapse

2021 ◽  
pp. 108447
Author(s):  
Miranda G. Greiner ◽  
Matisyahu Shulman ◽  
Tse-Hwei Choo ◽  
Jennifer Scodes ◽  
Martina Pavlicova ◽  
...  
Keyword(s):  
Opioid Use Disorder ◽  
Opioid Use ◽  
Medication Status

Interpersonal Trauma Among Women and Men Receiving Buprenorphine in Outpatient Treatment for Opioid Use Disorder

2021 ◽  
pp. 107780122110327
Author(s):  
Caitlin E. Martin ◽  
Anna Beth Parlier-Ahmad ◽  
Lori Beck ◽  
Nicholas D. Thomson
Keyword(s):  
Substance Use ◽  
Interpersonal Trauma ◽  
Opioid Use Disorder ◽  
Sex And Gender ◽  
Opioid Use ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
And Gender ◽  
Public Health Strategies

People with opioid use disorder (OUD) are vulnerable to negative health outcomes related to substance use and psychosocial issues, such as interpersonal trauma (IPT). Participants receiving buprenorphine completed a cross-sectional survey (July–September 2019). OUD outcomes were prospectively abstracted over a 28-week timeframe. More than a third reported recent IPT (40% women, 36% men). Sexual violence was more common among women than men ( p = .02). For women only, IPT was associated with substance use during follow-up (β = 20.72, 95% CI: 4.24, 37.21). It is important for public health strategies in the opioid crisis to address IPT using sex- and gender-informed approaches.

Captagon use in a patient with iatrogenic opioid use disorder

2021 ◽  
Vol 10 ◽  
Author(s):  
Mohammed Hamdan ◽  
Samer El Hayek ◽  
Maya Bizri
Keyword(s):  
Middle Eastern ◽  
Opioid Use Disorder ◽  
Opioid Withdrawal ◽  
Psychotic Symptoms ◽  
Patient Counseling ◽  
Opioid Use ◽  
Case Presentation ◽  
Recreational Use ◽  
Reducing Properties

Background: Captagon or Fenethylline is a synthetic theophylline derivative of amphetamine that is widely available for recreational use in the Middle East. It has pain-reducing properties and is known to induce restlessness, irritability, and psychotic symptoms. Case presentation: A middle-aged man with iatrogenic opioid use disorder was admitted for acute cholecystitis. A week following cholecystectomy, the patient used Captagon while hospitalized to manage opioid withdrawal pain. He experienced waxing and waning episodes of irritability, aggressiveness, disorganized behaviors, delusions, and hallucinations, all concurrent with his Captagon intake. These episodes were managed similarly to intoxication with other stimulant types. Conclusion: Careful patient counseling and close follow-up are essential when opioids are prescribed. Captagon’s pain-reducing properties make it an attractive and dangerous option for Middle Eastern patients suffering from opioid withdrawal. Captagon intoxication is currently managed similarly to other stimulant types, but more studies are needed to develop management guidelines specific to this substance.

scholarly journals Beyond Buprenorphine: Models of Follow-up Care for Opioid Use Disorder in the Emergeny Department

2020 ◽  
Vol 21 (6) ◽  
Author(s):  
Alister Martin ◽  
Kelley Butler ◽  
Tyler Chavez ◽  
Andrew Herring ◽  
Sarah Wakeman ◽  
...  
Keyword(s):  
Opioid Use Disorder ◽  
Opioid Use ◽  
Follow Up Care

A 3 year follow-up of HCV infection in opioid use disorder patients in treatment

2015 ◽  
Vol 156 ◽  
pp. e60
Author(s):  
Clotilde Duburque ◽  
V. Canva ◽  
Marc Auriacombe ◽  
P. Djomboue ◽  
B. Hernout ◽  
...  
Keyword(s):  
Opioid Use Disorder ◽  
Hcv Infection ◽  
Opioid Use

Laboratory-induced stress and craving predict opioid use during follow-up among individuals with prescription opioid use disorder

2021 ◽  
pp. 108755
Author(s):  
Tanya C. Saraiya ◽  
Amber Jarnecke ◽  
Jennifer Jones ◽  
Delisa G. Brown ◽  
Kathleen T. Brady ◽  
...  
Keyword(s):  
Opioid Use Disorder ◽  
Prescription Opioid ◽  
Opioid Use ◽  
Induced Stress ◽  
Prescription Opioid Use

scholarly journals Emergency-Department Initiated Buprenorphine: Impact on Quality of Life Factors

2021 ◽  
Author(s):  
Caleb Carroll ◽  
Delissa Hand ◽  
Whitney Covington ◽  
Joel Rodgers ◽  
Lauren A. Walter
Keyword(s):  
Quality Of Life ◽  
Emergency Department ◽  
Opioid Use Disorder ◽  
Treatment Programs ◽  
Opioid Use ◽  
Employment Rates ◽  
The Government ◽  
Retention In Treatment

Abstract Background: Emergency department (ED)-initiated medications for opioid use disorder (MOUD) have emerged as an effective strategy against the opioid epidemic. Opioid use disorder (OUD) patients engaged in ED-initiated MOUD programs have higher retention in treatment programs and improved outcomes with regard to overdose rates and mortality. It is unclear however, how engagement in ED-initiated MOUD programs might affect quality of life (QoL). We sought to describe demographic characteristics and QoL factors reported by patients engaged in ED-initiated MOUD and referral services. Methods: An ED MOUD-initiation program was launched in July 2019, with subsequent referral to definitive services. Enrolled patients were interviewed at intake, 3-months, and 6-months to ascertain QoL indices via the Government Performance and Results Act (GPRA) measures. Descriptive statistics and Fisher’s Exact were utilized to assess the data. Results: Through 12/2020, 89 participants were enrolled. The majority were white (85.4%), male (61.8%), and between the ages of 25-44 (75.3%). To-date, 31 participants (43.7% eligible) have completed 3-month follow-up and 28 (45.2% eligible) have competed 6-month follow-up. With regards to assessed QoL factors, over half demonstrated significant improvement, including 5 of 7 psychosocial factors, to include satisfaction with personal relationships, QoL self-rating, satisfaction with personal health, energy for everyday life, and satisfaction with self (p <.05). Financial needs met was the only objective QoL factor to demonstrate significant improvement during the follow-up time period. While not significant, homelessness also decreased, specifically 14 (15.7%) identified as homeless at intake as compared to one (3.7%) at 6-month follow-up. Additional trends toward decreased violence exposure and increased employment rates were also noted.Conclusions: In addition to decreasing illicit opioid drug use, maintenance of ED-initiated MOUD may positively impact broad QoL measures.

scholarly journals Comparison of LORETA Z Score Neurofeedback and Cognitive Rehabilitation in Terms of Their Effectiveness in Reducing Craving in Opioid Addicts

2021 ◽  
Author(s):  
Alireza Faridi ◽  
◽  
Farhad Taremian ◽  
Robert W Thatcher ◽  
Mohsen Dadashi ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Attentional Bias ◽  
Cognitive Rehabilitation ◽  
Opioid Use Disorder ◽  
Z Score ◽  
Opioid Use ◽  
Cognitive Rehabilitation Therapy ◽  
Post Test

Background: Previous studies have shown that conventional neurofeedback and cognitive modification treatments have led to numerous psychological improvements in patients suffering from substance use disorders. However, effectiveness of LORETA (Low-Resolution Brain Electromagnetic Tomography) Z score neurofeedback (LZNFB) and Cognitive rehabilitation therapy on reducing of opium craving has yet to be investigated. Thus, aim of the present study was to compare effectiveness of LZNFB and Cognitive rehabilitation therapy with methadone maintenance treatment (MMT) in reduction of opium craving in patients with opioid use disorder. Methods: Thirty patients with opioid use disorder undergoing MMT were randomly assigned into three groups: LZNFB with MMT, Cognitive rehabilitation with MMT (as experimental groups), and MMT alone Control group. The LZNFB and Cognitive rehabilitation groups received 20 and 15 sessions of treatment, respectively. The three groups were assessed using a number of questionnaires as well as Dot-Probe Task at pre-test, post-test, and one-month follow-up. Results: The results showed that both experimental groups accomplished significantly greater reduction in opium craving than MMT alone group at post-test and follow up (P<0.05). The LZNFB with MMT group showed higher decrease in opioid craving than the Cognitive rehabilitation with MMT group. In addition, Cognitive rehabilitation group experienced greater improvement on attentional bias towards craving cues than LZNFB with MMT group at post-test and follow up. Finally, LZNFB with MMT group and Cognitive rehabilitation with MMT group got higher scores on the recovery assessment scale than MMT alone group at post-test and follow up. According to results of this study, LZNFB training is more effective than Cognitive Rehabilitation in decreasing of craving and improving quality of life in addiction to opioids. Conclusion: The findings of the current study provided preliminary support for the effectiveness of LZNFB and Cognitive rehabilitation on reduction of opium craving, improvement of attentional bias towards craving cues and quality of life among Iranian opioids use patients.

scholarly journals The Effect of Single High-dose Buprenorphine on Opioid Craving and Relapse

2019 ◽  
Author(s):  
Jamshid Ahmadi ◽  
Mina SefidfardJahromi ◽  
Dara Ghahremani ◽  
Edythe D. London
Keyword(s):  
Statistical Significance ◽  
Opioid Use Disorder ◽  
Opioid Withdrawal ◽  
High Dose ◽  
Opioid Use ◽  
Single High Dose ◽  
High Doses ◽  
Long Acting ◽  
Drug Free

Abstract Background: Buprenorphine, a treatment for Opioid Use Disorder, has liability for diversion and abuse. Use of single high doses of buprenorphine that are supervised avoid issues with diversion that occur with unsupervised or take home doses. Such doses have the potential to act as an initial opioid detox, facilitate transition to opioid antagonists or drug free treatments, as well as to maintenance treatment. Objective: To assess effects of a single, physician-administered high dose of buprenorphine on craving and on early relapse. Method: Sixty men who used heroin, opium or prescription opioids and met DSM-5 criteria for Opioid Use Disorder received a single, sublingual dose of buprenorphine (32 mg, 64 mg or 96 mg; n’s = 20, 21, and 19) as inpatients on a psychiatric unit. Buprenorphine was administered when patients were in moderate opioid withdrawal (4-5 symptoms). Self-reports of craving were taken at baseline and daily for the next 13 days, and relapse was assessed 1 and 2 months. Findings: Craving was reduced from baseline in each of the three groups (p < 0.0005), but the doseXtime interaction did not reach statistical significance (p= 0.069). Follow-up assessments at 1- and 2-months indicated significantly lower relapse rates for the higher-dose groups than for the low-dose group (p < 0.05). Conclusions: A single high dose of buprenorphine provides rapid relief of opioid craving and positively impacts relapse rate in the initial 1- and 2-months of outpatient treatment. Further investigation of single high-dose buprenorphine for early treatment of patients with Opioid Use Disorder is warranted as an alternative when buprenorphine/naloxone or long-acting buprenorphine dosage forms are not available. Keywords: Buprenorphine; opioid dependence; opioid withdrawal; craving

Sign in / Sign up

Export Citation Format

Share Document